These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28727946)

  • 21. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.
    Chen JY; Lin CY; Wang CM; Lin YT; Kuo SN; Shiu CF; Chang SW; Wu J; Sheen IS
    Genes Immun; 2011 Jun; 12(4):300-9. PubMed ID: 21346780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
    de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
    PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
    Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.
    Keshvari M; Alavian SM; Behnava B; Pouryasin A; Sharafi H
    J Res Med Sci; 2016; 21():72. PubMed ID: 27904617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
    Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil.
    de Seixas Santos Nastri AC; de Mello Malta F; Diniz MA; Yoshino A; Abe-Sandes K; Dos Santos SE; de Castro Lyra A; Carrilho FJ; Pinho JR
    Arch Virol; 2016 Jun; 161(6):1477-84. PubMed ID: 26973228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?
    O'Brien TR; Jackson SS
    J Interferon Cytokine Res; 2019 Oct; 39(10):618-626. PubMed ID: 31161939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
    Galmozzi E; Aghemo A
    J Clin Virol; 2014 Apr; 59(4):274-5. PubMed ID: 24495847
    [No Abstract]   [Full Text] [Related]  

  • 37. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    Meissner EG; Bon D; Prokunina-Olsson L; Tang W; Masur H; O'Brien TR; Herrmann E; Kottilil S; Osinusi A
    J Infect Dis; 2014 Jun; 209(11):1700-4. PubMed ID: 24367041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection.
    Waldenström J; Kåberg M; Alanko Blomé M; Widell A; Björkman P; Nilsson S; Hammarberg A; Weiland O; Nyström K; Lagging M
    Scand J Gastroenterol; 2021 Jul; 56(7):855-861. PubMed ID: 34034600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.